Daniel Allen Gold sold $26M of ROIV
director at Roivant Sciences Ltd.. 1,300,000 shares at an average of $20.23, traded Nov 19, 2025, filed Nov 21, 2025.
Score components
- +15RoleDirector
- +25Trade size$26.3M at market
- 0Share of holdings soldSold 6.7% of holdings
- +15Cluster5 insiders selling within 14 days
What happened after comparable sells
Same side and tier, against the S&P 500, at 1, 3 and 6 months. Shown to Pro users; the whole table is on the backtest page.
Price around the trade, and since
From a quarter before the trade to today. The arrow is the trade, the circle the day the filing reached EDGAR, which is the first day anyone outside could act; the dotted line is the S&P 500 rebased to that day's close.
Daily candles, adjusted for splits and dividends. Green arrows are insider buys, red are sells, sized by value; the dashed line is the close on the filing day, the dotted line SPY rebased to it.Charts by TradingView Lightweight Charts™
Rows in this filing
Every transaction in Form 4 0001193125-25-291731, as filed. Open on EDGAR
| Date | Transaction | Shares | Price | Value | Holdings after | Filed |
|---|---|---|---|---|---|---|
| Nov 19, 2025 | SOpen-market sale Common Sharesindirect: Held by QVT Financial Investment Cayman Ltd. | -850,000 | $20.25 | $17M | 18,497,727 | Nov 21, 2025 |
| Nov 19, 2025 | SOpen-market sale Common Sharesindirect: Held by QVT Financial Investment Cayman Ltd. | -150,000 | $20.20 | $3.0M | 18,347,727 | Nov 21, 2025 |
| Nov 19, 2025 | SOpen-market sale Common Sharesindirect: Held by QVT Financial Investment Cayman Ltd. | -125,000 | $20.16 | $2.5M | 18,222,727 | Nov 21, 2025 |
| Nov 19, 2025 | SOpen-market sale Common Sharesindirect: Held by QVT Financial Investment Cayman Ltd. | -175,000 | $20.24 | $3.5M | 18,047,727 | Nov 21, 2025 |
Related signals
Other insiders at Roivant Sciences Ltd. and this insider’s other filings.
| Score | Company | Insider | Value | Holdings | Filed |
|---|---|---|---|---|---|
| 28Weak | Roivant Sciences Ltd. | Epperly Melissa B director | $641k 17,750 shares | -54% | |
| 28Weak | Roivant Sciences Ltd. | Eric Venker President & Immunovant CEO | $7.3M 200,000 shares | -11% | |
| 25Weak | Roivant Sciences Ltd. | Epperly Melissa B director | $196k 4,938 shares | -33% | |
| 20Weak | Roivant Sciences Ltd. | Meghan Fitzgerald director | $203k 5,112 shares | -12% | |
| 27Weak | Roivant Sciences Ltd. | Meghan Fitzgerald director | $798k 20,000 shares | -32% | |
| 28Weak | Roivant Sciences Ltd. | Eric Venker President & Immunovant CEO | $7.2M 200,000 shares | -11% | |
| 60Notable | Roivant Sciences Ltd. | Meghan Fitzgerald director | $1.9M 70,000 shares | -62% | |
| 35Weak | Roivant Sciences Ltd. | Eric Venker President & Immunovant CEO | $5.6M 200,000 shares | -11% | |
| 75Notable | Roivant Sciences Ltd. | Epperly Melissa B director | $1.2M 41,861 shares | -73% | |
| 30Weak | Roivant Sciences Ltd. | Frank Torti President and Vant Chair | $82M 3,000,000 shares | -20% |
Not investment advice. Scores and forward returns are decision support built from public SEC filings and past prices; they describe what happened after comparable filings, not what will happen after this one. Do your own research and size your risk.